Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT.
published in: Journal for Immunotherapy of Cancer
date of publication: 2013-11-07
main subject: immunotherapy
Cites articles
There is nothing here
Article - wd:Q46561809